Psychopharmacology  ||| S:0 E:19 ||| NNP
and  ||| S:19 E:23 ||| CC
adverse  ||| S:23 E:31 ||| JJ
effects  ||| S:31 E:39 ||| NNS
of  ||| S:39 E:42 ||| IN
antipsychotic  ||| S:42 E:56 ||| JJ
long-acting  ||| S:56 E:68 ||| JJ
injections ||| S:68 E:78 ||| NNS
:  ||| S:78 E:80 ||| :
a  ||| S:80 E:82 ||| DT
review  ||| S:82 E:89 ||| NN
Depot  ||| S:89 E:95 ||| NNP
antipsychotics  ||| S:95 E:110 ||| NNS
are  ||| S:110 E:114 ||| VBP
widely  ||| S:114 E:121 ||| RB
used  ||| S:121 E:126 ||| VBN
in  ||| S:126 E:129 ||| IN
clinical  ||| S:129 E:138 ||| JJ
practice ||| S:138 E:146 ||| NN
.  ||| S:146 E:148 ||| .
Long-acting  ||| S:148 E:160 ||| JJ
formulations  ||| S:160 E:173 ||| NNS
of  ||| S:173 E:176 ||| IN
second-generation  ||| S:176 E:194 ||| JJ
antipsychotics  ||| S:194 E:209 ||| NNS
are  ||| S:209 E:213 ||| VBP
now  ||| S:213 E:217 ||| RB
being  ||| S:217 E:223 ||| VBG
developed  ||| S:223 E:233 ||| VBN
and  ||| S:233 E:237 ||| CC
introduced ||| S:237 E:247 ||| VBD
.  ||| S:247 E:249 ||| .
To  ||| S:249 E:252 ||| TO
review  ||| S:252 E:259 ||| VB
the  ||| S:259 E:263 ||| DT
pharmacology ||| S:263 E:275 ||| NN
,  ||| S:275 E:277 ||| ,
pharmacokinetics  ||| S:277 E:294 ||| NN
and  ||| S:294 E:298 ||| CC
adverse  ||| S:298 E:306 ||| JJ
effect  ||| S:306 E:313 ||| NN
profiles  ||| S:313 E:322 ||| NNS
of  ||| S:322 E:325 ||| IN
currently  ||| S:325 E:335 ||| RB
available  ||| S:335 E:345 ||| JJ
antipsychotic  ||| S:345 E:359 ||| JJ
long-acting  ||| S:359 E:371 ||| JJ
injections  ||| S:371 E:382 ||| NNS
( ||| S:382 E:383 ||| -LRB-
LAIs ||| S:383 E:387 ||| NNP
) ||| S:387 E:388 ||| -RRB-
.  ||| S:388 E:390 ||| .
The  ||| S:390 E:394 ||| DT
psychopharmacological  ||| S:394 E:416 ||| JJ
properties  ||| S:416 E:427 ||| NNS
of  ||| S:427 E:430 ||| IN
first-  ||| S:430 E:437 ||| JJ
and  ||| S:437 E:441 ||| CC
second-generation  ||| S:441 E:459 ||| JJ
antipsychotic  ||| S:459 E:473 ||| JJ
LAIs  ||| S:473 E:478 ||| NNS
are  ||| S:478 E:482 ||| VBP
reviewed  ||| S:482 E:491 ||| VBN
using  ||| S:491 E:497 ||| VBG
data  ||| S:497 E:502 ||| NNS
available  ||| S:502 E:512 ||| VBP
up  ||| S:512 E:515 ||| RP
to  ||| S:515 E:518 ||| TO
October  ||| S:518 E:526 ||| NNP
2008 ||| S:526 E:530 ||| CD
.  ||| S:530 E:532 ||| .
First-generation  ||| S:532 E:549 ||| JJ
antipsychotic  ||| S:549 E:563 ||| NNS
( ||| S:563 E:564 ||| -LRB-
FGA ||| S:564 E:567 ||| NNP
)  ||| S:567 E:569 ||| -RRB-
LAIs  ||| S:569 E:574 ||| NNS
are  ||| S:574 E:578 ||| VBP
associated  ||| S:578 E:589 ||| VBN
with  ||| S:589 E:594 ||| IN
a  ||| S:594 E:596 ||| DT
high  ||| S:596 E:601 ||| JJ
rate  ||| S:601 E:606 ||| NN
of  ||| S:606 E:609 ||| IN
acute  ||| S:609 E:615 ||| JJ
and  ||| S:615 E:619 ||| CC
chronic  ||| S:619 E:627 ||| JJ
movement  ||| S:627 E:636 ||| NN
disorders ||| S:636 E:645 ||| NNS
.  ||| S:645 E:647 ||| .
Risperidone  ||| S:647 E:659 ||| NNP
LAI  ||| S:659 E:663 ||| NNP
is  ||| S:663 E:666 ||| VBZ
better  ||| S:666 E:673 ||| JJR
tolerated  ||| S:673 E:683 ||| NN
in  ||| S:683 E:686 ||| IN
this  ||| S:686 E:691 ||| DT
respect ||| S:691 E:698 ||| NN
,  ||| S:698 E:700 ||| ,
but  ||| S:700 E:704 ||| CC
is  ||| S:704 E:707 ||| VBZ
associated  ||| S:707 E:718 ||| VBN
with  ||| S:718 E:723 ||| IN
hyperprolactinaemia  ||| S:723 E:743 ||| NN
and  ||| S:743 E:747 ||| CC
weight  ||| S:747 E:754 ||| NN
gain ||| S:754 E:758 ||| NN
.  ||| S:758 E:760 ||| .
Olanzapine  ||| S:760 E:771 ||| NNP
LAI  ||| S:771 E:775 ||| NNP
causes  ||| S:775 E:782 ||| VBZ
weight  ||| S:782 E:789 ||| NN
gain  ||| S:789 E:794 ||| NN
and  ||| S:794 E:798 ||| CC
other  ||| S:798 E:804 ||| JJ
metabolic  ||| S:804 E:814 ||| JJ
effects  ||| S:814 E:822 ||| NNS
but  ||| S:822 E:826 ||| CC
appears  ||| S:826 E:834 ||| VBZ
not  ||| S:834 E:838 ||| RB
to  ||| S:838 E:841 ||| TO
be  ||| S:841 E:844 ||| VB
associated  ||| S:844 E:855 ||| VBN
with  ||| S:855 E:860 ||| IN
an  ||| S:860 E:863 ||| DT
important  ||| S:863 E:873 ||| JJ
incidence  ||| S:873 E:883 ||| NN
of  ||| S:883 E:886 ||| IN
movement  ||| S:886 E:895 ||| NN
disorders ||| S:895 E:904 ||| NNS
.  ||| S:904 E:906 ||| .
Dosing  ||| S:906 E:913 ||| NNP
of  ||| S:913 E:916 ||| IN
LAIs  ||| S:916 E:921 ||| NNP
is  ||| S:921 E:924 ||| VBZ
complicated  ||| S:924 E:936 ||| VBN
by  ||| S:936 E:939 ||| IN
delayed  ||| S:939 E:947 ||| JJ
release  ||| S:947 E:955 ||| NN
of  ||| S:955 E:958 ||| IN
drug ||| S:958 E:962 ||| NN
,  ||| S:962 E:964 ||| ,
changes  ||| S:964 E:972 ||| NNS
in  ||| S:972 E:975 ||| IN
plasma  ||| S:975 E:982 ||| JJ
levels  ||| S:982 E:989 ||| NNS
without  ||| S:989 E:997 ||| IN
change  ||| S:997 E:1004 ||| NN
in  ||| S:1004 E:1007 ||| IN
dose ||| S:1007 E:1011 ||| NN
,  ||| S:1011 E:1013 ||| ,
and  ||| S:1013 E:1017 ||| CC
by  ||| S:1017 E:1020 ||| IN
the  ||| S:1020 E:1024 ||| DT
lack  ||| S:1024 E:1029 ||| NN
of  ||| S:1029 E:1032 ||| IN
data  ||| S:1032 E:1037 ||| NNS
establishing  ||| S:1037 E:1050 ||| VBG
clear  ||| S:1050 E:1056 ||| JJ
dose  ||| S:1056 E:1061 ||| NN
requirements ||| S:1061 E:1073 ||| NNS
.  ||| S:1073 E:1075 ||| .
All  ||| S:1075 E:1079 ||| DT
LAIs  ||| S:1079 E:1084 ||| JJ
offer  ||| S:1084 E:1090 ||| NN
the  ||| S:1090 E:1094 ||| DT
prospect  ||| S:1094 E:1103 ||| NN
of  ||| S:1103 E:1106 ||| IN
assured  ||| S:1106 E:1114 ||| JJ
adherence  ||| S:1114 E:1124 ||| NNS
( ||| S:1124 E:1125 ||| -LRB-
although  ||| S:1125 E:1134 ||| IN
patients  ||| S:1134 E:1143 ||| NNS
may  ||| S:1143 E:1147 ||| MD
still  ||| S:1147 E:1153 ||| RB
default  ||| S:1153 E:1161 ||| VB
on  ||| S:1161 E:1164 ||| IN
treatment ||| S:1164 E:1173 ||| NN
)  ||| S:1173 E:1175 ||| -RRB-
but  ||| S:1175 E:1179 ||| CC
their  ||| S:1179 E:1185 ||| PRP$
use  ||| S:1185 E:1189 ||| NN
is  ||| S:1189 E:1192 ||| VBZ
complicated  ||| S:1192 E:1204 ||| VBN
by  ||| S:1204 E:1207 ||| IN
adverse  ||| S:1207 E:1215 ||| JJ
effects ||| S:1215 E:1222 ||| NNS
,  ||| S:1222 E:1224 ||| ,
complex  ||| S:1224 E:1232 ||| JJ
pharmacokinetics  ||| S:1232 E:1249 ||| NN
and  ||| S:1249 E:1253 ||| CC
confusion  ||| S:1253 E:1263 ||| NN
over  ||| S:1263 E:1268 ||| IN
dose-response  ||| S:1268 E:1282 ||| JJ
relationships ||| S:1282 E:1295 ||| NNS
.  ||| S:1295 E:1297 ||| .
